Trefoil Therapeutics Raises $28M and Eyes the Clinic for Cornea Drug
Xconomy
JULY 16, 2019
Trefoil Therapeutics, which is developing treatments for diseases that affect the cornea, the outermost layer of the eye, has raised $28 million to move its lead drug candidate into human testing. The company is developing an engineered form of fibroblast growth factor-1 proteins (FGF-1) as a treatment for corneal diseases such as Fuchs’ dystrophy , which gradually causes endothelial cells within the cornea to die, leading to blurred vision that can eventually necessitate a corneal transplant.
Let's personalize your content